Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy
- PMID: 35923092
- DOI: 10.1093/eurheartj/ehac397
Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy
Conflict of interest statement
Conflict of interest: T.E. is consultant and stockholder of Dinaqor AG in Schlieren, Switzwerland (EHT technique) and participates in a strategic partnership of UKE and Evotec AG (EHT for cardiac repair).
Comment on
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.Eur Heart J. 2022 Sep 21;43(36):3477-3489. doi: 10.1093/eurheartj/ehac305. Eur Heart J. 2022. PMID: 35728000 Free PMC article.